FLT3 and acute myeloid leukemia: From further evaluation of the 139 childhood AML cases with low FLT3/ITD AR, survival analysis demonstrated that SCT conferred no impact on prognosis when compared with chemotherapy-only recipients (5-year EFS: 46% (18.9%) vs. 39.8% (11.4%), P = 0.18; 5-year OS: 53.4% (27%) vs. 54.5% (20.3%), P = 0.64; Fig. 5A, B).